Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 451Melanoma 287Squamous Cell Carcinoma of Head and Neck 229Parkinson Disease 4, Autosomal Dominant Lewy Body 188Neoplasms 180Triple Negative Breast Neoplasms 162Breast Neoplasms 161Neoplasm Metastasis 156Lung Neoplasms 141Colorectal Neoplasms 140Carcinoma, Renal Cell 129Head and Neck Neoplasms 120Stomach Neoplasms 103Ovarian Neoplasms 101Carcinoma, Transitional Cell 92Urinary Bladder Neoplasms 80Pancreatic Neoplasms 80Endometrial Neoplasms 74Carcinoma, Hepatocellular 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 48Sarcoma 43Carcinoma 42Small Cell Lung Carcinoma 39Glioblastoma 39Carcinoma, Squamous Cell 39Hodgkin Disease 36Lymphoma 34

Interventions

Nivolumab 2pembrolizumab 1pazopanib 1elacestrant 1dactolisib 1Specimen Handling 1Sirolimus 1Radiotherapy 1Radiation 1RAD1901 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Injections 1Ifosfamide 1Doxorubicin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Perivascular Epithelioid Cell Neoplasms × pembrolizumab × Clear all
NCT07089992 2026-05-14

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
32 enrolled
Sarcoma

Liposarcoma, Sarcoma, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡